register

News & Trends - Pharmaceuticals

Can Bayer’s Eylea gain an edge over Roche’s Vabysmo in wet AMD?

Health Industry Hub | October 18, 2023 |

Pharma News: Bayer’s Eylea (aflibercept) at a higher dosage could emerge as a worthy competitor to Roche’s Vabysmos (faricimab), a product that has rapidly gained market share for wet age-related macular degeneration (AMD) since securing PBS listing in January this year.

Real-world data indicates that wet AMD patients receive fewer anti-VEGF injections than the desired number (approximately seven) and experience worse visual outcomes compared with patients receiving fixed, frequent therapy in randomised controlled trials. Therefore, longer-acting therapies will overcome the treatment burden often associated with patient drop out, as well as other issues like macular scarring or fibrosis.

Results from Bayer/Regeneron’s phase 3 PULSAR trial in wet AMD showed that administering Eylea at the higher dose of 8 mg every 12 or 16 weeks was just as effective in vision improvement as the standard 2 mg dosage given every 8 weeks.

The PULSAR study spanning 96-weeks involved over 1,000 patients with treatment-naïve wet AMD (also called neovascular age-related macular degeneration (nAMD)). The study revealed promising results regarding the efficacy of Eylea at the higher dose. Administered at 8 mg every 12 or 16 weeks, the therapy demonstrated noninferiority in vision gains when compared to the standard 2 mg dosage given every 8 weeks. Eighty eight percent (88%) of participants achieved a dosing interval of 12 weeks or more by the study’s conclusion, with 78% maintaining this interval consistently over the two-year period. Moreover, 71% met extension criteria for even longer dosing intervals, including 47% for ≥20-week intervals and 28% for 24-week intervals, demonstrating the potential for extended treatment intervals with this higher dose regimen.

Comparatively, the two-year data from Roche’s Susvimo Archway study showed that a large proportion of Vabysmo patients can be kept on 12 weekly treatment (14.7%) and 16 weekly treatment (63.1%), resulting in the published 77.8% combined data. 

Additionally, earlier this year, data from the phase 3 BALATON and COMINO studies indicated that Roche’s Vabysmo showcased an advantage over Eylea in retinal vein occlusion (RVO), revealing reduced blood vessel leakage in the retina. This advantage extends to diabetic macular oedema (DME) and AMD, showcasing a drier retina with decreased swelling and fluid, which typically translates to clearer vision.

In response, Bayer stated, “The Vabysmo studies versus Eylea are non-inferiority studies, and Vabysmo has yet to demonstrate superiority over Eylea in the treatment of diabetic macular oedema, wet age macular degeneration, and retinal vein occlusion.”

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.


Human Resources

Decoding Novartis' blueprint for AI-powered workforce and a reimagined workplace: International HR Day 2025

Decoding Novartis’ blueprint for AI-powered workforce and a reimagined workplace: International HR Day

Health Industry Hub | May 16, 2025 |

As International HR Day (20 May) spotlights the theme HumanifyAI – Leading Change in a Dynamic World, Saada McNamee, Country […]

More


Medical and Science

What powers GenesisCare’s bold path in cancer research: Clinical Trials Day

What powers GenesisCare’s bold path in cancer research: Clinical Trials Day

Health Industry Hub | May 16, 2025 |

What does it take to deliver research that truly changes lives? For Sonya McColl, National Research Manager of Oncology at […]

More


News & Trends - MedTech & Diagnostics

Are we chasing value-based healthcare while ignoring the elephant in the hospital corridor?

Are we chasing value-based healthcare while ignoring the elephant in the hospital corridors?

Health Industry Hub | May 16, 2025 |

The health system is stuck in a volume-driven framework that rewards throughput over quality. It’s a model that no longer […]

More


News & Trends - MedTech & Diagnostics

Former APHA CEO joins day hospitals group amid strategic growth phase

Former APHA CEO joins day hospitals group amid strategic growth phase

Health Industry Hub | May 16, 2025 |

Cura Day Hospitals Group has announced the appointment of Michael Roff, former CEO of the Australian Private Hospitals Association (APHA), […]

More


This content is copyright protected. Please subscribe to gain access.